|
|
 |
|
Viewing report
|
|
|
|
Strategic Outlook On Protein Kinase Inhibitors in Oncology
Bioseeker, Feb 2006, Pages: 104
Since the discovery that the v-Src oncogene encoded a protein kinase in 1978, kinases have become a targeted therapy strategy in oncology for the pharmaceutical industry. The perfect date between Gleevec and Chronic Myeloid Leukemia (CML) will be hard to achieve by other inhibitors currently in development, because of CMLïs strong link to a sole pathogenic event - the Philadelphia chromosome. Thus, it is expected that multiple inhibitors may have to be used together to effect higher cure rates in cancers with multiple genetic abnormalities.
Scope of this report
- Drugs according to protein kinase target; Dual or multiple kinase inhibitor analysis
- Targets according to indication
- Competitive landscape assessment
- Protein kinase inhibitors on market
- Thorough review of the seven largest cancer indications in the field of protein kinase inhibitors
Research and analysis highlights
The number of protein kinase inhibitor (PKI) drugs has risen sharply, as the number of targets. The fiercest competition in PKI drug development is found in breast, lung, leukemia, prostate, and colorectal cancer. Several big pharma companies are out hunting for promising technology and drugs to complement their internal pipeline.
Key reasons to read this report
- Understand the clinical and strategic challenges to the commercialization of protein kinase inhibitor treatments
- Assess opportunities and risks for the continued development of innovative developmental treatments
- Adopt knowledge from this analysis to drive strategic planning decisions in oncology drug developmentTable of Contents
Methodology
The information structure in this report is based on our tactical information surveillance tool. Companies have been identified through the extensive information surveillance of more than 10 000 life science companies that represent the groundwork of our in-house company database. The analysis is based upon public information during 2003-2005. The amount of information varies, since established big pharmaceutical companies on the market, generally expose less information, as part of their business strategy. In contrast to small biotech companies, whose success is dependent on more direct exposure and on establishing themselves in the existing market.
|
|
|
|
